# DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

> clinical trial · VERIFIED · 2026-07-08

Status: ACTIVE_NOT_RECRUITING · Sponsor: Criterium, Inc. · Condition: Breast Cancer

- Company: Criterium, Inc.
- Sector: Breast Cancer
- Primary source: https://clinicaltrials.gov/study/NCT04567420

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.